Memorial Sloan Kettering Cancer Center Demonstrates Promising CAR T Cell Therapy Against Solid Tumors & AML

A team of clinical investigators at Memorial Sloan Kettering Cancer Center (MSKCC) have developed and conducted a first-in-human, Phase 1 clinical trial investigating regionally delivered, autologous, and mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Led by Principal Investigator Prasad S. Adusumilli the study targeted subjects with malignant pleural diseases—comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), dangerous aggressive cancers that lead often to short survival periods and death. The New York City-based MSKCC reports positive results of an early-stage Phase 1 study indicating the administration of the MSKCC-developed CAR T-therapy in 27 patients (25 with MPM) was safe and well-tolerated. The study team also included the PD-1 blocker pembrolizumab (Keytruda), treating 18 MPM patients safely. The MSKCC team reports that the CAR T-cell infusion led to an overall average survival measurement of 23.9 months (1-year overall survival 83%). Moreover, the investigators were able to sustain stable disease status for ≥6 months in 8 patients while they report two patients “exhibited complete metabolic response on PET scan.” ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee